Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | MMP13 | P45452 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5339633 | 0.84 | PKM (0.63) | MEN1KMT2ATDP1HSP90AA1ALDH1A1 | |
| SCHEMBL14900328 | 0.84 | TDP1 (0.75) | MEN1KMT2ATDP1HSP90AA1ALDH1A1 | |
| SCHEMBL108263 | 0.82 | ALDH1A1 (0.92) | MEN1KMT2ATDP1HSP90AA1ALDH1A1 | |
| SCHEMBL6781831 | 0.81 | HSP90AA1 (0.82) | MEN1KMT2ATDP1HSP90AA1ALDH1A1 | |
| SCHEMBL2958885 | 0.80 | HSP90AA1 (0.76) | MEN1KMT2ATDP1HSP90AA1ALDH1A1 | |
| SCHEMBL4925396 | 0.80 | MEN1 (0.84) | MEN1KMT2ATDP1HSP90AA1ALDH1A1 | |
| SCHEMBL1042327 | 0.80 | RAB9A (0.78) | MEN1KMT2ATDP1ALDH1A1NPC1 | |
| SCHEMBL13988420 | 0.80 | TDP1 (0.67) | MEN1KMT2ATDP1HSP90AA1ALDH1A1 | |
| SCHEMBL5338191 | 0.78 | MEN1 (0.80) | MEN1KMT2AALDH1A1NPC1HSD17B10 | |
| SCHEMBL10054206 | 0.78 | ALDH1A1 (0.68) | MEN1KMT2AALDH1A1HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109714-A1 | NEURODEGENERATIVE DISEASE THERAPEUTIC AGENT | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2013-05-02 | — | — | US | disclosed |
| US-20130109714-A1 | NEURODEGENERATIVE DISEASE THERAPEUTIC AGENT | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109714-A1 | NEURODEGENERATIVE DISEASE THERAPEUTIC AGENT | SNCA, NLN, GAP43 | MEN1 4500/4885KMT2A 3716/4885TDP1 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.